BRUSSELS (AP) — The European Commission said Thursday it has fined Israeli generic drugmaker Teva more than 460 million euros ($500 million) for improperly seeking to protect the patent for its ...

Last year, Teva was ordered to pay $225 million to settle price fixing charges in the U.S. related to sales of a cholesterol-lowering drug. Article Topic Follows: AP National News Jump to comments ↓ ...

Shares of Teva Pharmaceutical Industries Ltd. (TEVA) have gained 2.9% over the past four weeks to close the last trading session at $18.25, but there could still be a solid upside left in the ...

For more present picks (and the rest of our Father’s Day gift guides), check out all of the best gift ideas of 2024. If your dad gave you a spiel about how he “doesn’t need anything but your ...

In the latest quarter, 4 analysts provided ratings for Teva Pharmaceutical Indus (NYSE:TEVA), showcasing a mix of bullish and bearish perspectives. The table below provides a snapshot of their ...

Teva gets a buy rating as it trades well below 10-year highs and shows growth potential as the leading global generic drugmaker. Their drug pipeline is robust and diverse, as well as existing ...

Barclays raised the firm’s price target on Teva (TEVA) to $25 from $22 and keeps an Overweight rating on the shares. The firm introduced Olanzapine into its model, noting TEV-749’s sales ...